Therachon
Webb26 mars 2024 · We gave two presentations on investigational apraglutide for the treatment of #ShortBowelSyndrome at #ASPEN19!1. Complete Ph 1 trial results 2. Data from head-to-head rat studies comparing apraglutide to other GLP-2 analogs. WebbTherachon is a global biotechnology company (headquartered in Basel) committed to making a difference in the lives of patients living with serious rare conditions. Therachon …
Therachon
Did you know?
Webb8 jan. 2024 · The founders of Swiss biotech Therachon have launched a new company called VectivBio, also based in Basel, with €31M funding to develop drugs for rare … Webb8 maj 2024 · Under the terms of the agreement, Pfizer will acquire Therachon for $340 million upfront with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46 for the treatment of achondroplasia, a genetic condition and the most common form of short …
Webb1 juli 2024 · Early clinical development program for achondroplasia augments Pfizer’s Rare Disease portfolio ... April 13, 2024 Webb17 aug. 2024 · Therachon, a Swiss biotech company, has closed a $60 million round to fund its new developments in rare genetic disease treatments.
Webb29 nov. 2024 · Apraglutide, with once-weekly administration, is a potential best-in-class therapeutic for the treatment of short bowel syndrome. BASEL, Switzerland, Nov. 29, 2024 /PRNewswire/ -- Therachon AG ... WebbDevelopment group, serving as its Global Head for Integration Management and Global Head of Alliance Management. His work included the integration of Wyeth, Hospira, Anacor, Medivation, Therachon, Array and most recently Amplyx. He also directly led the separation of. 09 Apr 2024 21:53:51
WebbECHOPULSE. FOR FIBROADENOMA AND THYROID NODULES. ECHOPULSE® is a completely non-invasive robot for echotherapy treatment of thyroid nodules and breast …
Webb9 maj 2024 · May 9, 2024 - Updated on June 24, 2024. 2 minutes. Pharma giant Pfizer is acquiring the Swiss biotech Therachon, which is developing a protein drug to boost bone growth in the genetic condition achondroplasia. Pfizer will pay €303M ($340M) upfront, and up to €420M ($470M) dependent on Therachon reaching milestones in the development … iodophor stainless steelWebbTherachon Holding AG The Company, through its subsidiaries, provides therapeutic treatments for devastating rare conditions. Therachon Holding serves patients in … iodopropynyl butylcarbamate sdsWebbTherachon 1,172 followers on LinkedIn. Life-Transforming Therapies - Developing novel therapeutics for serious rare conditions Therachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is significant unmet medical need. iodoplatinate cas noWebb31 jan. 2024 · The investigational drug, one of an early generation drummed up by the buzzy AI tools in biotech, works by inhibiting multiple tropomyosin-related kinases, which … iodophor with alcoholWebb8 maj 2024 · Therachon is a clinical-stage global biotechnology company focused on the discovery and development of innovative treatment for severe, rare conditions with … onslow county bus locatorWebb17 aug. 2024 · Swiss-based biotech company, Therachon, which focuses on developing rare genetic disease treatments, says it has closed a $60 million round of funding as the company moves closer to a drug trial. The funding will be used to develop the company’s treatment for achondroplasia, the most common form of short limbed dwarfism, and … onslow county busted mugshotsWebb8 maj 2024 · Therachon is developing it as a weekly subcutaneous injection for children and adolescents with the disorder. The drug has finished Phase I trials. The European … onslow county booking photos